INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Tax withholdingVerified data

McCulloch Kevin reported XERS

See Remarks · Xeris Biopharma Holdings, Inc. · Common Stock

Side
F
Value
$223K
Shares
30.3K
Price
$7.36
Executed
Jan 31, 2026
Disclosed
Feb 2, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Jan 31 executedFeb 2, 2026 disclosed

XERS · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
8/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Tax withholding — administrative, little informational value

  • Relative size+4 / 25

$223K reported value · 1.8% of prior position

  • Filing timing0 / 15

    Disclosed 1 business day after execution (deadline: 2)

  • Historical behavior+4 / 15

    1 prior trade recorded in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · XERS

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    14
    PS
    Pieper StevenSee Remarks
    XERSXeris Biopharma Holdings, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$51K
    5,000 sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    21
    HB
    Hecht BethSee Remarks
    XERSXeris Biopharma Holdings, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$256K
    25.0K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    14
    MK
    McCulloch KevinSee Remarks
    XERSXeris Biopharma Holdings, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$153K
    15.0K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    9
    TM
    Taddese MenassieDirector
    XERSXeris Biopharma Holdings, Inc.
    Grant or award
    		A—
    22.4K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    15
    TM
    Taddese MenassieDirector
    XERSXeris Biopharma Holdings, Inc.
    Grant or award
    		A$320K
    31.5K sh
    		Nov 2, 2026Nov 4, 2026
    traded Nov 2, 2026
    		+2dSEC FORM 4

    Evidence

    7
    MK
    McCulloch KevinSee Remarks
    XERSXeris Biopharma Holdings, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$250K
    25.0K sh
    		Sep 28, 2026Sep 29, 2026
    traded Sep 28, 2026
    		+1dSEC FORM 4

    Evidence

    9
    MK
    McCulloch KevinSee Remarks
    XERSXeris Biopharma Holdings, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$127K
    15.0K sh
    		Sep 1, 2026Sep 1, 2026
    traded Sep 1, 2026
    		+0dSEC FORM 4

    Evidence

    6
    PS
    Pieper StevenSee Remarks
    XERSXeris Biopharma Holdings, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$43K
    5,000 sh
    		Sep 1, 2026Sep 1, 2026
    traded Sep 1, 2026
    		+0dSEC FORM 4

    Evidence

    18
    MK
    McCulloch KevinSee Remarks
    XERSXeris Biopharma Holdings, Inc.
    Tax withholding
    		F$177K
    21.9K sh
    		Aug 1, 2026Aug 21, 2026
    traded Aug 1, 2026
    		+20dSEC FORM 4

    Evidence

    25
    SP
    Shannon John Patrick JrDirector, See Remarks
    XERSXeris Biopharma Holdings, Inc.
    Tax withholding
    		F$296K
    36.6K sh
    		Aug 1, 2026Aug 21, 2026
    traded Aug 1, 2026
    		+20dSEC FORM 4

    Evidence

    1
    PS
    Pieper StevenSee Remarks
    XERSXeris Biopharma Holdings, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$43K
    5,000 sh
    		Aug 12, 2026Aug 12, 2026
    traded Aug 12, 2026
    		+0dSEC FORM 4

    Evidence

    13
    PS
    Pieper StevenSee Remarks
    XERSXeris Biopharma Holdings, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$148K
    17.4K sh
    		Jul 6, 2026Jul 7, 2026
    traded Jul 6, 2026
    		+1dSEC FORM 4

    Evidence

    9
    PS
    Pieper StevenSee Remarks
    XERSXeris Biopharma Holdings, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$235K
    27.6K sh
    		Jul 7, 2026Jul 7, 2026
    traded Jul 7, 2026
    		+0dSEC FORM 4

    Evidence

    16
    MK
    McCulloch KevinSee Remarks
    XERSXeris Biopharma Holdings, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$723K
    90.0K sh
    		Jul 1, 2026Jul 2, 2026
    traded Jul 1, 2026
    		+1dSEC FORM 4

    Evidence

    0
    PM
    Persky MarlaDirector
    XERSXeris Biopharma Holdings, Inc.
    Grant or award · 10b5-1 plan
    		A$203K
    33.0K sh
    		Jun 4, 2026Jun 5, 2026
    traded Jun 4, 2026
    		+1dSEC FORM 4

    Evidence

    13
    KG
    Kong GarhengDirector
    XERSXeris Biopharma Holdings, Inc.
    Grant or award
    		A—
    24.2K sh
    		Jun 4, 2026Jun 5, 2026
    traded Jun 4, 2026
    		+1dSEC FORM 4

    Evidence

    8
    BA
    Brady James AloysiusDirector
    XERSXeris Biopharma Holdings, Inc.
    Grant or award
    		A$203K
    33.0K sh
    		Jun 4, 2026Jun 5, 2026
    traded Jun 4, 2026
    		+1dSEC FORM 4

    Evidence

    12
    KG
    Kong GarhengDirector
    XERSXeris Biopharma Holdings, Inc.
    Grant or award
    		A$203K
    33.0K sh
    		Jun 4, 2026Jun 5, 2026
    traded Jun 4, 2026
    		+1dSEC FORM 4

    Evidence

    13
    BA
    Brady James AloysiusDirector
    XERSXeris Biopharma Holdings, Inc.
    Grant or award
    		A—
    24.2K sh
    		Jun 4, 2026Jun 5, 2026
    traded Jun 4, 2026
    		+1dSEC FORM 4

    Evidence

    12
    PM
    Persky MarlaDirector
    XERSXeris Biopharma Holdings, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$91K
    15.5K sh
    		Jun 3, 2026Jun 5, 2026
    traded Jun 3, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002031695-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jan 31, 2026
    Published
    Feb 2, 2026
    Ingested by INSIDER
    Nov 5, 04:19 UTC
    Last re-read
    Nov 5, 04:19 UTC

    Extracted facts

    Filer
    McCulloch Kevin
    Role
    See Remarks
    Transaction
    Tax withholdingAs filed: “F”
    Asset
    Xeris Biopharma Holdings, Inc.
    Ticker
    XERS
    Shares
    30.3K
    Price per share
    $7.36
    Value
    $222,927
    Execution date (reported)
    Jan 31, 2026
    Owned after transaction
    1.76M shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 30.3K
    • Price: $7.36

    = $222,927

    What this establishes

    McCulloch Kevin filed this Form 4 reporting a tax withholding of XERS on Jan 31, 2026. It became public on Feb 2, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    See Remarks
    McCulloch Kevincik:0002031695
    Issuer
    Xeris Biopharma Holdings, Inc.cik:0001867096

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.